{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:24Z","timestamp":1786991304129,"version":"build-2736575974"},"reference-count":28,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2120264","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:38:04Z","timestamp":1662709084000},"page":"1110-1117","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Place of care and costs associated with acute episodes and remission in bipolar I disorder"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Higa","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan V.","family":"Doan","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Amari","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oliveri","sequence":"additional","affiliation":[{"name":"Genesis Research, Hoboken, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillard","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.10.003"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31544-0"},{"issue":"8","key":"e_1_3_6_5_1","first-page":"467","article-title":"Improving functioning, quality of life, and well-being in patients with bipolar disorder","volume":"22","author":"Bonnin CDM","year":"2019","unstructured":"Bonnin CDM, Reinares M, Martinez-Aran A, et\u00a0al. Improving functioning, quality of life, and well-being in patients with bipolar disorder. Int J Neuropsychopharmacol. 2019;22(8):467\u2013477.","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.09.061"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.08.030"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S259338"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.09.011"},{"key":"e_1_3_6_10_1","unstructured":"Culpepper L Higa S Martin A et\u00a0al. Reduced health-related quality of life and increased costs associated with bipolar I disorder. Poster presented at the Psych Congress. San Antonio TX; 2021."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01148.x"},{"issue":"3","key":"e_1_3_6_12_1","first-page":"7","article-title":"Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening","volume":"40","author":"Hirschfeld RM","year":"2007","unstructured":"Hirschfeld RM, Calabrese JR, Frye MA, et\u00a0al. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull. 2007;40(3):7\u201314.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000499"},{"key":"e_1_3_6_14_1","unstructured":"Allergan. Vraylar\u00ae (cariprazine) prescribing information. Madison (NJ); 2019."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822090-00006"},{"key":"e_1_3_6_16_1","unstructured":"Intra-Cellular Therapies Announces US FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults. Intra-Cellular Therapies. [cited 2021 Dec 20]. Available from: https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/intra-cellular-therapies-announces-us-fda-approval-caplytar."},{"key":"e_1_3_6_17_1","unstructured":"Alembic Pharmaceuticals. Lurasidone hydrochloride prescribing information. Bridgewater (NJ); 2019."},{"key":"e_1_3_6_18_1","unstructured":"ACI Healthcare. Quetiapine extended release prescribing information. Cora Springs (FL); 2021."},{"key":"e_1_3_6_19_1","unstructured":"Novartis Pharmaceuticals Corporation. Clozaril\u00ae prescribing information. East Hanover (NJ); 2014."},{"key":"e_1_3_6_20_1","unstructured":"Florida Medicaid Drug Therapy Management Program for Behavioral Health University of South Florida College of Behavioral & Community Sciences. Psychotherapeutic Medication Guidelines for Adults 2019-2020. Agency for Health Care Administration State of Florida; 2019. Available from: https:\/\/floridabhcenter.org\/."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S227196"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743719900460"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196974"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0891988712436684"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119050-00004"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(14)70003-5"},{"issue":"6","key":"e_1_3_6_27_1","first-page":"379","article-title":"Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics","volume":"5","author":"Bergeson JG","year":"2012","unstructured":"Bergeson JG, Kalsekar I, Jing Y, et\u00a0al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits. 2012;5(6):379\u2013386.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0317"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v6.i4.399"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2120264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:19:53Z","timestamp":1729163993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2120264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2120264"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2120264","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}